News Release

Malaria vaccine shows 87% efficacy in clinical trial

In a UW Medicine-partnered phase 1 trial, the Sanaria PfSPZ-LARC2 Vaccine safely blocked infection in 87% of participants exposed to live malaria parasites

Reports and Proceedings

University of Washington School of Medicine/UW Medicine

Thin blood smear of Plasmodium falciparum-infected blood

image: 

A thin blood smear of Plasmodium falciparum-infected blood

view more 

Credit: Sean C. Murphy

The novel, genetically attenuated whole parasite PfSPZ-LARC2 Vaccine for malaria achieved an 87% efficacy rate in preventing infection during a recent phase 1 trial.

Among 22 participants exposed to a controlled malaria challenge 12 to 16 weeks after their last dose of vaccine, all seven placebo recipients became infected while only two of 15 vaccinated individuals developed an infection. All infected participants were safely and promptly treated. In addition, the vaccine was safe and well tolerated in the vaccinated participants.

These breakthrough findings were presented today at the annual meeting of the American Society of Tropical Medicine and Hygiene in Washington, D.C. They were reported by Dr. Sean C. Murphy, professor of laboratory medicine and pathology at the University of Washington School of Medicine and medical director, Department of Laboratories, Seattle Children’s Hospital.

The recently completed trial was conducted by UW Medicine and its partners as part of the Infectious Diseases Clinical Research Consortium, or IDCRC, and was sponsored by the National Institutes of Health’s National Institute of Allergy and Infectious Diseases.

The trial began enrollment in the summer of 2025. The study's co-principal investigators, along with Murphy, are Dr. Jim Kublin of the Fred Hutch Cancer Center’s Vaccine and Infectious Disease Division, and Dr. R. Scott McClelland, professor of medicine, epidemiology and global health at UW School of Medicine, who led clinical site operations at Harborview Medical Center's Virology Research Clinic.

Because there are over 600,000 deaths worldwide each year from malaria, vaccines that completely block infection — rather than just reduce symptom severity — are urgently needed.

The attenuated PfLARC2 strain was created in Dr. Stefan Kappe’s laboratory at Seattle Children’s. Kappe is now director of the Center for Vaccine Development and Global Health at the University of Maryland School of Medicine in Baltimore.Co-inventors also include former lab member Dr. Debashree Goswami and Dr. Ashley Vaughan at Seattle Children’s. The strain was further developed, manufactured, and advanced to the clinical stage by Sanaria Inc.

“We engineered the PfLARC2 strain with the goal to have a safe vaccine that stimulates a superior response against malaria parasite infection in the liver. It is truly rewarding to see that this vaccine is safe and how well it has protected against challenge with a highly divergent malaria strain in the Seattle trial,” Kappe said.

This live-attenuated vaccine exposes the human immune system to a wide assortment of parasite proteins and grows like a normal malaria parasite until two genetic deletions in the vaccine safely halt the parasite's growth during its liver stage.

"This study was made possible by the culmination of decades' worth of research on the biology of Plasmodium parasites and the maturation of genetic engineering technologies that allowed scientists to modify the parasite genome to make it safe for use in humans and yet tuned just right to induce strong protective immune responses," Murphy said.

The study’s "challenge" design meant that the vaccine’s efficacy was tested by deliberately exposing vaccinated and placebo-treated participants to live malaria parasites under carefully controlled conditions. This study’s test of efficacy was notable because of the long gap between immunization and challenge (12 to 16 weeks) and the use of a variant malaria strain in the challenge itself. This required the PfSPZ-LARC2 Vaccine to achieve durable, cross-strain immunity in order to provide protection.

The ability to protect across variant strains is important since the P. falciparum parasite is geographically diverse, and it is important for the vaccine to be protective everywhere that malaria is transmitted. In this trial, the vaccine strain used is from West Africa, and the challenge strain is from Brazil.

"It takes a strong and well-coordinated clinical trial team with excellent laboratory resources and with highly engaged and committed research participants to carry out these kind of studies," McClelland said.

Kublin noted that Seattle has a unique testing facility for participants and an altruistic study population that make human challenge studies possible. "Our teams at UW Medicine and Fred Hutch have been conducting malaria human challenge studies since 2011 and have used the model to provide important insights about new drugs and vaccines," Kublin said.

Highly sensitive assaying for these studies is provided by the UW Medicine Malaria Molecular Diagnostic Laboratory, which Murphy directs.

"We look forward to continuing to advance this vaccine and other promising products that can combat malaria using our unique clinical trial resources here in Seattle," Murphy said.

The study was conducted by the IDCRC (UM1AI148684) and the Vaccine and Treatment Evaluation Unit (VTEU) at the University of Washington School of Medicine (UM1AI148573). The IDCRC and network of VTEUs are supported by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. Sanaria Inc. is a biotechnology company based in Rockville, Maryland, focused on research, development, manufacture, and commercialization of whole-parasite PfSPZ malaria vaccines to prevent malaria infection and transmissio


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.